Market Overview

UPDATE: Valeant Plunges 7% After Bearish Wells Fargo Report

Related VRX
Attention Biotech Investors: February PDUFA Catalysts Come Calling
42 Biggest Movers From Yesterday
Earnings Preview: Valeant Pharmaceuticals (Seeking Alpha)

Valeant's stock has reacted to Wells Fargo's latest analysis of the company, seen below on Benzinga Pro.


Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) opened for trading on Friday at $90.48 and moved lower throughout the morning trading session. After nearly 2 full hours of trading, the stock had lost more than 7 percent and hit an intra-day low of $69.33.

Valeant closed for trading at $94.11 on Thursday.

Investors were reacting to a negative report by Wells Fargo's David Maris who initiated coverage of Valeant with an Unperform rating and valuation range of $65 to $68, implying a potential downside of more than 40 percent.

Related Link: Valeant Has 42% Downside And Too Many Questions, Wells Fargo Warns

Maris also suggested that Valeant had a 58 percent chance of bankruptcy last year based on an Altman z-score analysis. According to Maris, an Altman Z-score below 1.8 is a signal of financial distress, and Valeant's Altman Z-score has been below this threshold for each of the last five years.

Valeant's current score is only 0.79, which suggests a bankruptcy probability of 58.4 percent.

Latest Ratings for VRX

Jan 2018Goldman SachsInitiates Coverage OnSell
Dec 2017JP MorganDowngradesNeutralUnderweight
Nov 2017Deutsche BankMaintainsHold

View More Analyst Ratings for VRX
View the Latest Analyst Ratings

Posted-In: Analyst Color News Short Ideas Health Care Analyst Ratings Movers Trading Ideas General


Related Articles (VRX)

View Comments and Join the Discussion!